Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With Relapsed/Refractory Small Cell Lung Cancer

Trial Profile

A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With Relapsed/Refractory Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2018

At a glance

  • Drugs AMG-119 (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions; First in man
  • Sponsors Amgen
  • Most Recent Events

    • 05 Nov 2018 Planned End Date changed from 9 Sep 2020 to 30 Aug 2020.
    • 05 Nov 2018 Planned primary completion date changed from 9 Sep 2020 to 30 Aug 2020.
    • 26 Sep 2018 Trial design presented at the 19th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top